.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Farmers Insurance
Julphar
AstraZeneca
Express Scripts
Merck
Argus Health
Chinese Patent Office
Moodys
Medtronic

Generated: December 12, 2017

DrugPatentWatch Database Preview

Ziprasidone mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for ziprasidone mesylate and what is the scope of ziprasidone mesylate patent protection?

Ziprasidone mesylate
is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ziprasidone mesylate has one hundred and twelve patent family members in forty-five countries and two supplementary protection certificates in one country.

There are twenty-one drug master file entries for ziprasidone mesylate. Three suppliers are listed for this compound.

Pharmacology for ziprasidone mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ziprasidone mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002► Subscribe► Subscribe
PfizerGEODONziprasidone mesylateINJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ziprasidone mesylate

Country Document Number Estimated Expiration
Poland188164► Subscribe
Hungary222451► Subscribe
Australia730856► Subscribe
Morocco24172► Subscribe
Turkey9802231► Subscribe
Egypt24401► Subscribe
Norway985193► Subscribe
Slovakia150598► Subscribe
African Regional IP Organization (ARIPO)9700978► Subscribe
Yugoslavia17297► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZIPRASIDONE MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2003004,C0904273Lithuania► SubscribePRODUCT NAME: ZIPRASIDONUM (5-(2-(4-(1,2-BENZIZOTIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CHLOR-1,3-DIHIDRO-2H-INDOL-2-ONAS); REGISTRATION NO/DATE: 02/7887/8 20021002
2003004Lithuania► SubscribePRODUCT NAME: ZIPRASIDONUM (5-(2-(4-(1,2-BENZIZOTIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CHLOR-1,3-DIHIDRO-2H-INDOL-2-ONAS); REGISTRATION NO/DATE: 02/7887/8 20021002
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Medtronic
Dow
Federal Trade Commission
Express Scripts
Mallinckrodt
Julphar
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot